Table 1. Characteristics of the EA patients.
| Anti-CarP negative (n = 406) | Anti-CarP low-positive (n = 68) | Anti-CarP high-positive (n = 74) | P (negative vs. positive) | P (low vs. high-positive) | |
|---|---|---|---|---|---|
| Female, n (%) | 328 (80.8) | 53 (77.94) | 62 (83.78) | 0.96 | 0.4 |
| Age, yrs., p50 [IQR] | 54.5 [42.0–67.5] | 54.8 [46.1–62.7] | 54.3 [44.0–64.8] | 0.6 | 0.7 |
| Smoking, n (%) | 0.4 | 0.6 | |||
| Never | 214 (54.6) | 34 (52.3) | 34 (47.2) | ||
| Ever | 94 (24.0) | 16 (24.6) | 16 (22.2) | ||
| Current | 84 (20.7) | 15 (23.1) | 22 (30.6) | ||
| BMI, p50 [IQR] | 26.0 [23.2–29.3] | 26.3 [23.5–29.2] | 26.2 [22.7–29.3] | 0.9 | 0.6 |
| Menopause (%) No/Yes/NA | 61.1/34.5/3.9 | 54.4/39.7/5.9 | 58.1/40.5/1.4 | 0.5 | 0.3 |
| European, n (%) | 353 (87.0) | 54 (79.4) | 57 (77.0) | 0.012 | 0.7 |
| Prednisone use, n (%) | 97 (24.0) | 14 (20.6) | 20 (27.0) | 0.3 | 0.4 |
| Cumulative prednisone, mg, p50 [IQR] | 0 [0–120] | 0 [0–83] | 0 [0–160] | 0.4 | 0.12 |
| Disease duration, mo, p50 [IQR] | 5.0 [2.6–8.2] | 6.2 [3.7–9.1] | 4.3 [2.7–7.0] | 0.8 | 0.011 |
| 2010 RA criteria, n (%) | 175 (43.1) | 53 (77.9) | 60 (81.1) | <0.001 | 0.6 |
| RF, n (%) | 133 (32.8) | 51 (75.0) | 53 (71.6) | <0.001 | 0.6 |
| ACPA, n (%) | 101 (25.8) | 45 (66.2) | 53 (73.6) | <0.001 | 0.3 |
| DAS28, p50 [IQR] | 4.0 [3.1–5.1] | 3.9 [2.9–5.2] | 4.8 [3.5–5.9] | 0.045 | 0.011 |
| HUPI, p50 [IQR] | 6.0 [4.0–9.0] | 6.5 [4.0–9.0] | 8.0 [6.0–10.0] | 0.016 | 0.046 |
| HAQ, p50 [IQR] | 0.9 [0.4–1.5] | 0.8 [0.3–1.4] | 1.0 [0.6–1.6] | 0.8 | 0.022 |
Abbreviations: n: number; IQR: interquartile range; p50: 50th percentile or median; SD: standard deviation; BMI: body mass index; NA: not available; HAQ: Health Assessment Questionnaire.